RenovoRx, Inc. (RNXT) Earnings growth forecast for next year

Public company logo of renovorx.com (RNXT)

RenovoRx, Inc. (RNXT) is expanding gastrointestinal tumor therapy through partnerships with oncology centers by implementing the RenovoCath system. The projected change in earnings per share for the coming year reflects expectation dynamics, where the metric value stands at 61.30. The RenovoTAMP platform strategy focuses on targeted drug delivery to reduce toxicity. FDA orphan status protects the local chemotherapy ecosystem, ensuring a steady influx of clinics and patients.

RNXT: RenovoRx Inc Expected earnings per share growth for next year 07/04/2022 - 11/17/2026

RenovoRx - analytical breakdowns and key metrics (RNXT)

- price and consensus price forecast:
Fundamental company analysis:RNXT, RenovoRx
Core merchandise of renovorx.com

This indicator measures the average expected change in earnings per share (EPS) for the coming year, neutralizing the time lags associated with quarterly reports. By analyzing the forward growth vector of EPS for the next year, an investor can identify asset overvaluation if the trend rises too sharply. For RenovoRx, Inc. (RNXT), with its narrow specialization in GI chemotherapy, this forecast reflects the binary risks of clinical trial success in the absence of current sales.